189 related articles for article (PubMed ID: 31994344)
1. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015.
Zhu Y; Yang R; Cai J; Yu J; Tang Y; Chen Y; Wang N; He H; Wu X; Cheng FWT; Sun L; He Y; Ju X; Tian X; Hu Q; Jin R; Pan K; Fang Y; Zhai X; Jiang H; Li CK
Cancer Med; 2020 Mar; 9(6):2113-2121. PubMed ID: 31994344
[TBL] [Abstract][Full Text] [Related]
2. Role of granulocyte colony-stimulating factor as adjunct therapy for septicemia in children with acute leukemia.
Liang DC; Chen SH; Lean SF
Am J Hematol; 1995 Feb; 48(2):76-81. PubMed ID: 7531394
[TBL] [Abstract][Full Text] [Related]
3. Pattern of bloodstream infections in patients with hematological malignancies in a tertiary care centre.
Bansal S; Advani SH
Indian J Cancer; 2014; 51(4):447-9. PubMed ID: 26842155
[TBL] [Abstract][Full Text] [Related]
4. Infections during induction therapy of childhood acute lymphoblastic leukemia--no association to mannose-binding lectin deficiency.
Lausen B; Schmiegelow K; Andreassen B; Madsen HO; Garred P
Eur J Haematol; 2006 Jun; 76(6):481-7. PubMed ID: 16494622
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.
Sulis ML; Blonquist TM; Stevenson KE; Hunt SK; Kay-Green S; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JG; Neuberg DS; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2018 May; 65(5):e26952. PubMed ID: 29319209
[TBL] [Abstract][Full Text] [Related]
6. Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group.
Dupuis LL; Lu X; Mitchell HR; Sung L; Devidas M; Mattano LA; Carroll WL; Winick N; Hunger SP; Maloney KW; Kadan-Lottick NS
Cancer; 2016 Apr; 122(7):1116-25. PubMed ID: 26773735
[TBL] [Abstract][Full Text] [Related]
7. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
8. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
9. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
[TBL] [Abstract][Full Text] [Related]
10. Infection-related complications during treatment for childhood acute lymphoblastic leukemia.
Inaba H; Pei D; Wolf J; Howard SC; Hayden RT; Go M; Varechtchouk O; Hahn T; Buaboonnam J; Metzger ML; Rubnitz JE; Ribeiro RC; Sandlund JT; Jeha S; Cheng C; Evans WE; Relling MV; Pui CH
Ann Oncol; 2017 Feb; 28(2):386-392. PubMed ID: 28426102
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of the Early Efficacy and Serious Adverse Events between CCCG-ALL 2015 and CCLG-ALL 2008 in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia].
Pan LL; Zheng YZ; LE SH; Hua XL; Zheng H; Chen ZS; Li J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Jun; 30(3):. PubMed ID: 35680796
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia.
Rosenfeld E; Getz KD; Miller TP; Seif AE; Fisher BT; Burrows E; Ramos MJ; De León DD; Aplenc R; Morales KH; Guevara JP
Pediatr Blood Cancer; 2022 Jun; 69(6):e29467. PubMed ID: 34811879
[TBL] [Abstract][Full Text] [Related]
14. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.
Lex C; Körholz D; Kohlmüller B; Bönig H; Willers R; Kramm CM; Göbel U
Support Care Cancer; 2001 Oct; 9(7):514-21. PubMed ID: 11680831
[TBL] [Abstract][Full Text] [Related]
15. Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China.
Cui L; Li ZG; Chai YH; Yu J; Gao J; Zhu XF; Jin RM; Shi XD; Zhang LP; Gao YJ; Zhang RD; Zheng HY; Hu SY; Cui YH; Zhu YP; Zou Y; Ng MHL; Xiao Y; Li JH; Zhang YH; He HL; Xian Y; Wang TY; Li CK; Wu MY;
Am J Hematol; 2018 Jul; 93(7):913-920. PubMed ID: 29675840
[TBL] [Abstract][Full Text] [Related]
16. Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies.
Rubio M; Palau L; Vivas JR; del Potro E; Diaz-Mediavilla J; Alvarez A; Martinez R; Picazo JJ
Infect Control Hosp Epidemiol; 1994 Feb; 15(2):101-4. PubMed ID: 8201230
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and clinical impact of thrombosis during induction chemotherapy for pediatric acute lymphoblastic leukemia: A report from CYP-C.
Pelland-Marcotte MC; Kulkarni K; Tran TH; Stammers D; Gupta S; Sung L; Athale UH
Am J Hematol; 2024 Feb; 99(2):274-283. PubMed ID: 38164978
[TBL] [Abstract][Full Text] [Related]
18. Minimal Residual Disease-guided Risk Restratification and Therapy Improves the Survival of Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Children's Hospital in China.
Liao C; Xu X; Shen D; Song H; Xu W; Zhao F; Yang S; Shi S; Liang J; Li S; Tang Y
J Pediatr Hematol Oncol; 2019 Aug; 41(6):e346-e354. PubMed ID: 30640823
[TBL] [Abstract][Full Text] [Related]
19. Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Lech-Maranda E; Seweryn M; Giebel S; Holowiecki J; Piatkowska-Jakubas B; Wegrzyn J; Skotnicki A; Kielbinski M; Kuliczkowski K; Paluszewska M; Jedrzejczak WW; Dutka M; Hellmann A; Flont M; Zdziarska B; Palynyczko G; Konopka L; Szpila T; Gawronski K; Sulek K; Sokolowski J; Kloczko J; Warzocha K; Robak T
Int J Infect Dis; 2010 Feb; 14(2):e132-40. PubMed ID: 19581118
[TBL] [Abstract][Full Text] [Related]
20. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
